PA) -- The University of Pennsylvania School of Medicine
is now one of only six Senator Paul D. Wellstone Muscular Dystrophy
Cooperative Research Centers in the United States. The Center at
Penn will be directed by H. Lee Sweeney, PhD, Chair
of the Department of Physiology at Penn; and co-directed by Kathryn
R. Wagner, MD, PhD, of The Johns Hopkins School of Medicine.
“This award will accelerate the pace of our translational
work and provide a pathway to patient trials,” says Sweeney,
in describing the work of the new Wellstone Muscular Dystrophy Cooperative
Research Center at Penn. “It will also be the nucleus of a
larger translational-research initiative for muscular dystrophies
that I hope to catalyze at Penn.”
All six Centers, which honor the memory of the late-Senator Wellstone-who
was a champion of muscular-dystrophy research and issues in Congress-are
funded by the Muscular Dystrophy Association and the following three
divisions within the National Institutes of Health: the National
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),
the National Institute of Neurological Disorders and Stroke (NINDS),
and the National Institute of Child Health and Human Development
Under Sweeney's leadership, the Penn-based Center will focus on
ways to increase muscle growth and examine compounds to inhibit
enzymes involved in the degradation of muscle tissue. The core facility,
located at Penn, will analyze muscular dystrophy (MD) animal models.
Planned clinical trials, to be based at NINDS in Bethesda, MD, will
determine the safety and feasibility of a potential drug treatment
for MD, which was first developed in Sweeney's research lab. Other
research sites, in addition to Johns Hopkins, that are contributing
to the investigations directed by the Penn Center are the University
of Florida/Gainesville, and the NINDS Intramural Research Program.
Muscular Dystrophy is characterized by progressive weakness and
degeneration of the skeletal or voluntary muscles that control movement.
Researchers at the Wellstone Centers study various forms of MD,
including Duchenne/Becker Muscular Dystrophy, Myotonic Dystrophy,
Facioscapulohumeral Dystrophy, and Limb-Girdle Muscular Dystrophy.
The two other most recently named Centers are the Children's National
Medical Center in Washington D.C. and at the University of Iowa.
The three new centers join centers at the University of Washington,
the University of Pittsburgh, and the University of Rochester. The
centers work individually and collaboratively and are guided by
a steering committee that includes representatives from each center.
Each has both basic and clinical research projects and one or more
core facilities to support them. Centers must also make core resources
or services available to the national muscular dystrophy research
PENN Medicine is a $2.7 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn’s School of Medicine is ranked #2 in the nation
for receipt of NIH research funds; and ranked #4 in the nation in
U.S. News & World Report’s most recent ranking of top
research-oriented medical schools. Supporting 1,400 fulltime faculty
and 700 students, the School of Medicine is recognized worldwide
for its superior education and training of the next generation of
physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System comprises: its
flagship hospital, the Hospital of the University of Pennsylvania,
consistently rated one of the nation’s “Honor Roll”
hospitals by U.S. News & World Report; Pennsylvania Hospital,
the nation's first hospital; Penn Presbyterian Medical Center; a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home health care and hospice.